Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.98
(-2.29%)
CNY 8.98
(-2.29%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.98 Billion CNY | -20.28% |
| 2022 | 3.74 Billion CNY | 77.96% |
| 2021 | 2.1 Billion CNY | 43.08% |
| 2020 | 1.47 Billion CNY | 5.18% |
| 2019 | 1.39 Billion CNY | -3.06% |
| 2018 | 1.44 Billion CNY | 8.51% |
| 2017 | 1.33 Billion CNY | 40.9% |
| 2016 | 943.94 Million CNY | 66.85% |
| 2015 | 565.74 Million CNY | 22.12% |
| 2014 | 463.26 Million CNY | 40.67% |
| 2013 | 329.33 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 2.66 Billion CNY | -5.25% |
| 2024 Q2 | 2.81 Billion CNY | -2.7% |
| 2024 Q1 | 2.89 Billion CNY | -3.08% |
| 2023 Q1 | 3.46 Billion CNY | -7.59% |
| 2023 FY | 2.98 Billion CNY | -20.28% |
| 2023 Q4 | 2.98 Billion CNY | -3.08% |
| 2023 Q3 | 3.08 Billion CNY | -4.31% |
| 2023 Q2 | 3.22 Billion CNY | -6.99% |
| 2022 FY | 3.74 Billion CNY | 77.96% |
| 2022 Q3 | 3.54 Billion CNY | 14.37% |
| 2022 Q2 | 3.1 Billion CNY | 25.49% |
| 2022 Q4 | 3.74 Billion CNY | 5.58% |
| 2022 Q1 | 2.47 Billion CNY | 17.44% |
| 2021 Q1 | 1.6 Billion CNY | 9.41% |
| 2021 Q3 | 1.98 Billion CNY | 16.98% |
| 2021 Q4 | 2.1 Billion CNY | 6.13% |
| 2021 FY | 2.1 Billion CNY | 43.08% |
| 2021 Q2 | 1.69 Billion CNY | 5.34% |
| 2020 Q4 | 1.47 Billion CNY | 3.46% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 1.47 Billion CNY | 5.18% |
| 2020 Q2 | 1.39 Billion CNY | 0.0% |
| 2020 Q3 | 1.42 Billion CNY | 2.03% |
| 2019 FY | 1.39 Billion CNY | -3.06% |
| 2019 Q4 | 1.39 Billion CNY | 0.0% |
| 2018 FY | 1.44 Billion CNY | 8.51% |
| 2017 Q1 | 1.43 Billion CNY | 51.9% |
| 2017 Q2 | 1.43 Billion CNY | 0.0% |
| 2017 FY | 1.33 Billion CNY | 40.9% |
| 2016 Q1 | 819.45 Million CNY | 44.84% |
| 2016 Q2 | 819.45 Million CNY | 0.0% |
| 2016 FY | 943.94 Million CNY | 66.85% |
| 2016 Q3 | 943.94 Million CNY | 15.19% |
| 2016 Q4 | 943.94 Million CNY | 0.0% |
| 2015 Q4 | 565.74 Million CNY | 0.0% |
| 2015 Q3 | 565.74 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 FY | 565.74 Million CNY | 22.12% |
| 2014 FY | 463.26 Million CNY | 40.67% |
| 2013 FY | 329.33 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 17.93 Billion CNY | 83.35% |
| Hangzhou Tigermed Consulting Co., Ltd. | 29.69 Billion CNY | 89.942% |
| Dirui Industrial Co.,Ltd. | 3.32 Billion CNY | 10.055% |
| Beijing Strong Biotechnologies, Inc. | 5.17 Billion CNY | 42.291% |
| Medicalsystem Biotechnology Co., Ltd. | 3.48 Billion CNY | 14.397% |
| Maccura Biotechnology Co.Ltd | 8.11 Billion CNY | 63.213% |
| Guangzhou Wondfo Biotech Co.,Ltd | 5.77 Billion CNY | 48.25% |
| Guangdong Hybribio Biotech Co.,Ltd. | 5.72 Billion CNY | 47.835% |
| BGI Genomics Co., Ltd. | 13.61 Billion CNY | 78.059% |
| Amoy Diagnostics Co., Ltd. | 1.93 Billion CNY | -54.369% |